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Abstract
OBJECTIVES: Controlled reoxygenation on starting cardiopulmonary bypass (CPB) rather than hyperoxic CPB may confer clinical advan-
tages during surgery for congenital cyanotic heart disease.
METHODS: A single-centre, randomized controlled trial was carried out to compare the effectiveness of controlled reoxygenation (nor-
moxia) versus hyperoxic CPB in children with congenital cyanotic heart disease undergoing open-heart surgery (Oxic-2). The co-primary
clinical outcomes were duration of inotropic support, intubation time and postoperative intensive care unit (ICU) and hospital stay.
Analysis of the primary outcomes included data from a previous trial (Oxic-1) conducted to the same protocol.
RESULTS: Ninety participants were recruited to Oxic-2 and 79 were recruited to the previous Oxic-1 trial. There were no significant differ-
ences between the groups for any of the co-primary outcomes: inotrope duration geometric mean ratio (normoxia/hyperoxic) 0.97, 95%
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ICU stay HR 1.14 95% CI (0.77–1.67), P-value = 0.52, hospital stay HR 0.90, 95% CI (0.65–1.25), P-value = 0.53. Lower oxygen levels were suc-
cessfully achieved during the operative period in the normoxic group. Serum creatinine levels were lower in the normoxic group at day 2,
but not on days 1, 3–5. Childhood developmental outcomes were similar. In the year following surgery, 85 serious adverse events were
reported (51 normoxic group and 34 hyperoxic group).
CONCLUSIONS: Controlled reoxygenation (normoxic) CPB is safe but with no evidence of a clinical advantage over hyperoxic CPB.
Clinical trial registration number: Current Controlled Trials—ISRCTN81773762.




GMR Geometric mean ratio
HR Hazard ratio
ICU Intensive care unit
PaO2 Oxygen partial pressure
PICU Paediatric intensive care unit




Cyanotic children undergoing open-heart surgery are particularly
susceptible to reoxygenation injury, arising from the intraopera-
tive reintroduction of high molecular oxygen levels on starting
cardiopulmonary bypass (CPB), prior to the ischaemic cardiople-
gic arrest [1, 2].
One strategy proposed to avoid reoxygenation injury is the use
of controlled reoxygenation with an oxygen partial pressure
(PaO2) that is similar to the patient’s preoperative oxygen satur-
ation (SaO2) on starting CPB [3, 4]. Ihnken et al. [5, 6] showed the
beneficial effects of normoxic reoxygenation in a clinical animal
model of acute hypoxaemia and in adult undergoing cardiac sur-
gery. More recently, Peng et al. [7] confirmed in an in vivo animal
model that controlled reoxygenation significantly reduced oxida-
tive stress, inflammation, apoptosis and myocardial injury com-
pared with hyperoxic reperfusion. We also provided direct
evidence that controlling reoxygenation can ameliorate the sys-
temic inflammatory and stress response associated with myocar-
dial, cerebral and hepatic injury, particularly in patients with
single ventricle physiology [8, 9]. Several studies have recom-
mended that a controlled reoxygenation strategy should be rou-
tinely used in cyanotic neonates, infants and children undergoing
cardiac surgical repairs that are at high risk of mortality and of
developing multiple organ failure after surgery [10–12]. We there-
fore hypothesized that controlled reoxygenation on starting CPB
rather than hyperoxic CPB confers clinical advantages during sur-
gery for congenital cyanotic heart disease. We report the results
of the Oxic-2 trial designed to compare the clinical effectiveness
of controlled reoxygenation versus hyperoxic CPB for surgery for
congenital cyanotic heart disease. We also combine the data
from Oxic-2 and a previous trial (Oxic-1), which was conducted
at the same institution and followed the same protocol for all
end points which were assessed in both studies [8, 9].
METHODS
Trial design
The Oxic-2 trial is a single-centre, parallel-group randomized
controlled trial with blinding. Participants were randomized to
receive CPB with either standard PaO2 (150–200 mmHg, hyper-
oxic group) or controlled PaO2 (matched to the patient, nor-
moxic group) in a 1:1 ratio. The Oxic-2 trial is registered with
Current Controlled Trials (ISRCTN81773762). Patients and the
public did not advise on the design, conduct or reporting of this
trial. All cyanotic children with SaO2 of less than or equal to 90%
having scheduled surgery to repair or palliate a congenital heart
abnormality using CPB were eligible to participate. Children
admitted for an emergency operation and those requiring pre-
operative cardiovascular or respiratory support were excluded.
Children who had a preoperative diagnosis of a developmental
disorder were eligible to join the trial, but were excluded from
the neurocognitive assessments.
The trial was approved by the South West—Central Bristol
Research Ethics Committee (reference 07/H0106/172) and
the UK Medicines and Healthcare products Regulatory
Agency (MHRA, EUDRACT reference 2010-019713-21). MHRA
approval was granted in 2010 after the start of the trial,
when, after Sponsor review, it confirmed that oxygen is con-
sidered an investigational medicinal product in the UK. The
University Hospitals Bristol NHS Foundation Trust sponsored
the trial.
Interventions
In the hyperoxic group, oxygen levels were maintained at 150–
200 mmHg at initiation of CPB and throughout surgery. This was
the locally agreed protocol. Oxygen levels of 150–200 mmHg are
high compared to the child’s usual oxygen levels. In the normoxic
group, the CPB was performed using air and minimum oxygen
to maintain the patient’s own preoperative SaO2 levels (i.e.
<90%). This was achieved by flushing the prime with nitrogen
(N2) just before starting CPB via a bacteriologic filter (0.2 lm)
at a rate of between 100 and 200 ml/min while the prime was
circulating at 1000 ml/min. An in-line partial pressure of
oxygen (PO2) monitor was used to measure the PO2 of the
prime (in air this will equilibrate at 150 mmHg). The patient’s
own PO2 levels were maintained for 10 min, then slowly raised
to 120 mmHg by 30 min and 150 mmHg by the end of CPB [8,
9]. All other aspects of the participants’ preoperative and post-
operative management were in accordance with the hospital
local protocols (www.uhbristol.nhs.uk, see Supplementary
Material).











The primary outcomes were (i) duration of inotropic support, (ii)
intubation time, (iii) paediatric intensive care unit (PICU) and (iv)
postoperative hospital stay (from date of surgery to discharge
from cardiac ward). Secondary clinical outcomes were hospital
mortality and morbidity measures; blood loss and transfusion
requirements; postoperative echocardiographic findings; postop-
erative blood tests results; renal function as measured by blood
urea nitrogen and creatinine levels assessed every 24 h for the
first 5 days after surgery; and a childhood developmental assess-
ment using the Bayley Scales of Infant Development (3rd edition,
BSID-III).
Sample size
In a pilot study in 32 cyanotic children given hyperoxic CPB, the
geometric mean duration of inotropic support was 69 h, with
standard deviation (SD) (on the logarithmic scale) 0.61. A sample
size of 90 patients per group was required to allow us to detect
an 18 h (or equivalently a 26% reduction) in mean duration with
90% power, assuming a 5% level of statistical significance (2-
tailed). Using estimates for ventilation time, PICU and hospital
stay from the same pilot study, a total sample size of 180 would
also be sufficient to detect a 32% reduction in ventilation time
(15 h), a 23% reduction in PICU stay (26 h) and a 17% reduction
in hospital stay (1.8 days). Clinical outcome data were collected
in the earlier Oxic-1 trial (n = 79), which was conducted at the
same institution and followed the same intervention protocol,
and Oxic-2 was designed with the intention that data from both
trials should contribute to the total sample size for the primary
outcomes, so 101 participants needed to be recruited to Oxic-2.
For these outcomes, data from both Oxic-1 and Oxic-2 are used.
Randomization
Randomization was stratified by age (<6 months, >_6 months).
Allocations were generated by computer using block randomiza-
tion with varying block sizes by a statistician independent of the
study team. A password-protected secure database concealed
allocations until data had been entered to confirm identity and
eligibility.
Blinding
Participants and their parents/guardians were blinded to the treat-
ment allocation. Surgeons, anaesthetists, perfusionists and nurses
involved in the operation were unblinded. Staff caring for partici-
pants in PICU and on the ward were not actively informed of the
participant’s study allocation. Echocardiographic findings were
interpreted by a cardiologist blinded to the treatment allocation.
Renal function analysis and developmental assessments using the
Bayley Scales of Infant Development were carried out by blinded
researchers. All other outcomes were ascertained directly from
medical notes, PICU charts and electronic hospital records.
Follow-up
Participants were followed up for safety for 1 year. Serious ad-
verse events after hospital discharge were collected via
questionnaire sent at 3 and 12 months. Where parents/guardians
did not respond, safety data were collected via the participant’s
General Practitioner.
Statistical analysis
Analyses were directed by a pre-specified statistical analysis plan
and performed on an intention-to-treat basis. Continuous data
are summarized using mean and SD, or median and interquartile
range/geometric mean and 95% confidence interval (CI) if distri-
butions are skewed. Categorical data are summarized as number
and percentage. Binary outcomes were compared using logistic
regression, continuous outcomes using linear regression, time to
event outcomes using Cox proportional hazards models (with
censoring for death) and continuous longitudinal outcomes using
mixed-effects models with patient fitted as a random effect and
an unstructured covariance structure for repeated measures.
Model fit was assessed via standard methods (e.g. graphical plots)
and if inadequate, then transformations were sought. Outcomes
analysed on a logarithmic scale were transformed back to the
original scale after analysis and results presented as geometric
mean ratios (GMRs). All analyses used the hyperoxic CPB as the
reference group were adjusted for age (<6 months vs >_6 months)
and baseline values where measured. The primary outcome anal-
yses also included trial phase (Oxic-1 or Oxic-2) and treatment x
phase interaction terms in the models and results are presented
by phase and overall. Sensitivity analyses were specified in the
statistical analysis plan, but not in the trial protocol: (i) replacing
intubation time, PICU and hospital stay with the maximum
observed time for patients who died, (ii) including any period of
reintubation in the intubation time, (iii) reanalysing inotropic
data including only dopamine usage, the only inotrope collected
in both Oxic-1 and Oxic-2, (iv) imputing missing presurgery
developmental scores and (v) modelling baseline and follow-up
developmental scores jointly (see Supplementary Material for
further details). One post hoc sub-group analysis was conducted,
comparing the primary outcomes for participants with more and
less severe cyanosis. Outcomes are reported as effect sizes with
95% CIs and likelihood ratio tests were used to determine statis-
tical significance. Analyses were performed in SAS version 9.3
(SAS Institute Inc., Cary, NC, USA) and Stata version 13.1
(StataCorp LP, College Station, TX, USA).
RESULTS
Recruitment
Between November 2003 and November 2007, a total of 79
patients consented to participate to the Oxic-1 trial and were
randomized (screening data unavailable). Between May 2008 and
May 2014, a total of 216 patients were screened for inclusion in
the Oxic-2 trial, 49 of whom were found to be ineligible. In total,
169 patients were approached to join the trial and 90 patients
agreed, provided written informed consent and their child was
randomized (53%). Combining the Oxic-1 and Oxic-2 trials, 83
participants were allocated to the hyperoxic (standard) treatment
and 86 to normoxic (experimental) treatment (Fig. 1).
The primary analysis includes all randomized participants,
there were no withdrawals. There were 6 treatment cross-overs
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randomized and treated but ineligible, as they were participating
in another trial (Supplementary Material, Table S1). Oxic-1 partic-
ipants were followed up to hospital discharge only. Oxic-2
participants were followed up for 12 months after randomization.
Safety data to 12 months were collected for 77/90 (86%) Oxic-2
participants.
Figure 1: Flow of participants.











The median age of participants in Oxic-2 was 10.5 months
(interquartile range 5.3–40.8) and 49/90 (54%) participants
were male. Incidentally, in the hyperoxic group, there were
proportionally more male children (64% vs 46%) and a higher
proportion who had undergone cardiac surgery previously
(64% vs 50%). The majority of participants were undergoing ei-
ther total cavopulmonary connection (22/90; 24%), tetralogy
of Fallot (22/90; 24%) or a Glenn shunt (31/90; 34%).
Overall, all characteristics were generally well balanced across
the treatment groups (Table 1 and Supplementary Material,
Table S2). Participants in Oxic-1 were on average 3.9 months
older and included proportionally more tetralogy of Fallot
procedures (31/79, 39%).
Operative details
The CPB and cross-clamp times in Oxic-2 were, on average,
16 min longer in the normoxic group than in the hyperoxic
group (CPB duration median 104 vs 88 min; cross-clamp duration
median 85 vs 69 min), although the median operation duration
was just over 3.5 h in both groups (Table 1 and Supplementary
Material, Table S3). Cardioplegia was required for 23/43
Table 1: Participant characteristics and operative details
Oxic2 Oxic1
Randomized to
hyperoxic (n = 44)
Randomized to
normoxic (n = 46)
Randomized to
hyperoxic (n = 39)
Randomized to
normoxic (n = 40)
n % n % n % n %
Demography
Age (months), median (IQR) 10.8 (5.6–51.6) 10.4 (5.1–25.2) 14.2 (4.8–51.8) 14.7 (6.1–39.6)
Male gender 28/44 63.6 21/46 45.7 23/39 59.0 26/40 65.0
Height (cm),a median (IQR) 72.0 (63.5–102.0) 72.5 (65.0–87.0) 76.0 (67.0–100.0) 75.5 (63.5–94.5)
Weight (kg), median (IQR) 8.7 (6.3–15.6) 8.4 (6.2–12.0) 9.8 (6.4–16.0) 9.2 (6.6–12.8)
Diagnoses/surgery
TAPVD 0/44 0.0 0/46 0.0 2/39 5.1 2/40 5.0
TCPC 12/44 27.3 10/46 21.7 8/39 20.5 9/40 22.5
TGA 1/44 2.3 1/46 2.2 5/39 12.8 7/40 17.5
TOF 10/44 22.7 12/46 26.1 16/39 41.0 15/40 37.5
Glenn shunt 16/44 36.4 15/46 32.6 8/39 20.5 7/40 17.5
VSD 0/44 0.0 2/46 4.3
ASD 2/44 4.5 1/46 2.2
AVSD 0/44 0.0 2/46 4.3
Damus–Kaye–Stansel 3/44 6.8 3/46 6.5
Rastelli procedure 3/44 6.8 1/46 2.2
Mustard operation 0/44 0.0 2/46 4.3
Tricuspid valve repair 0/44 0.0 2/46 4.3
Other surgery/diagnoses 3/44 6.8 6/46 13.0
Other characteristics
Heart rhythm
Sinus rhythm 40/42 95.2 46/46 100.0 38/38 100.0 37/37 100.0
AF 1/42 2.4 0/46 0.0 0/38 0.0 0/37 0.0
Heart block 0/42 0.0 0/46 0.0 0/38 0.0 0/37 0.0
Paced 1/42 2.4 0/46 0.0 0/38 0.0 0/37 0.0
Previous cardiac surgery requiring sternotomy 21/33 63.6 18/36 50.0
O2 saturations (%),
b median (IQR) 81 (75.5–86.0) 79 (76.0–83.0)
Duration of surgery
Duration of surgeryc (min), median (IQR) 207 (167–265) 206 (165–274)
Duration of bypass (min), median (IQR) 88 (64–121) 104 (66–131)
Cardioplegia
Cardioplegia used 23/43 53.5 26/45 57.8 26/39 66.7 28/39 71.8
Cumulative cross-clamp timed 69 (40–94) 85 (72–100) 56 (41–74) 52 (33–68)
Other operative details
Defibrillation 5/42 11.9 2/43 4.7 1/38 2.6 1/35 2.9
Transannular patch used 10/33 30.3 10/36 27.8
Intraoperative IABP 3/43 7.0 0/46 0.0
Pacing post bypass 8/42 19.0 7/43 16.3
Missing data (Oxic2 hyperoxic, Oxic2 normoxic, Oxic1 hyperoxic, Oxic1 hormoxic).
a11 patients (1, 5, 1, 4).
b73 patients (36, 37, -, -); information was not collected for the first 73 Oxic-2 participants.
c49 patients (21, 28, -, -).
d5 patients (0, 5, 0, 0).
AF: atrial fibrillation; ASD: atrial septal defect; AVSD: atrioventricular septal defect; IQR: interquartile range; TAPVD: total anomalous pulmonary venous defect;
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(53%) participants in the hyperoxic group and 26/45 (58%) in the
normoxic group. Cross-clamp times were similar in both groups.
Primary outcomes
Treatment estimates for the 4 primary outcomes are shown in
Fig. 2. The duration of intubation was similar in the 2 groups [me-
dian 20 h in the hyperoxic group vs 19 h in the normoxic group,
hazard ratio (HR) 1.03, 95% CI 0.74–1.42; P = 0.873], and did not
differ between Oxic-1 and Oxic-2 (P = 0.906, Supplementary
Material, Table S4). Duration of PICU stay was on average 2 h
shorter in the normoxic group (median 49 vs 51 h, HR 1.14, 95%
CI 0.77–1.67; P = 0.518). Postoperative hospital stay was similar in
the 2 groups (median 9 days in the hyperoxic group and 10 days
in the normoxic group, HR 0.90, 95% CI 0.65–1.25; P = 0.533),
and was similar between Oxic-1 and Oxic-2 (P = 0.683). All partic-
ipants in the Oxic-2 trial required inotropic support, with dopa-
mine most frequently used in both groups (Supplementary
Material, Table S5). The maximum duration of inotropic support
was slightly longer in the normoxic group, but not significantly so
(median 37 vs 26 h, GMR 1.03, 95% CI 0.73–1.46; P = 0.867).
Sensitivity analyses replacing intubation time, PICU and hos-
pital stay with the maximum observed time for patients who
died, including any period of reintubation in the intubation time
and reanalysing inotropic data considering only dopamine usage
did not substantially alter the treatment estimates or change
conclusions (Supplementary Material, Tables S6–S8). Results were
also similar for the subgroups of participants with more and less
severe cyanosis (Supplementary Material, Fig. S1).
Secondary outcomes
There were 3 deaths following surgery, 1 in the hyperoxic and 2
in the normoxic group. Similar numbers of patients experienced
1 or more complication in the period to hospital discharge in the
2 groups (28/46; 61% in the normoxic group vs 22/44; 50% in the
hyperoxic group, odds ratio 1.58, 95% CI 0.68–3.65; P = 0.287,
Fig. 3 and Supplementary Material, Table S9). The median total
blood loss was similar in both groups (178 ml in the hyperoxic
group vs 170 ml in the normoxic group, GMR 1.01, 95% CI 0.73–
1.38; P = 0.972).
Lower oxygen levels (pO2) were successfully achieved during
the operative period for participants in the normoxic group (10
min post start CPB GMR = 0.54, 95% CI 0.43–0.68; 30 min post
start CPB GMR = 0.93, 95% CI 0.77–1.12 and 10 min post end
CPB GMR = 0.92, 95% CI 0.63–1.35; Fig. 4). Differences in creatin-
ine levels between the groups varied over time (treatment x time
interaction P = 0.040); the mean level was 14% lower in the nor-
moxic group on day 2 (GMR = 0.86, 95% CI 0.75–1.00) (Fig. 5A
and Supplementary Material, Table S10). Urea levels were lower
in the normoxic group across the first 5 postoperative days, but
not significantly so (GMR 0.94, 95% CI 0.83–1.08; P = 0.39, Fig. 5B
and Supplementary Material, Table S10). Serial blood gases
measurements and tests carried out as part of usual care are
summarized in Supplementary Material, Figs S2–S8; profiles of
test results over time were similar between the groups. Few par-
ticipants had a decrease in ventricular function after surgery
(3/25; 12% in the hyperoxic group and 2/27; and 7% in the nor-
moxic group respectively, Supplementary Material, Table S11).
Figure 2: Primary outcome results. Numbers in brackets are the 95% confi-
dence interval. GMR: geometric mean ratio; HR: hazard ratio; ICU: intensive
care unit.
Figure 3: Secondary outcome results. Numbers in brackets are the 95% confi-
dence interval. Oxic-2 trial only. GMR: geometric mean ratio; OR: odds ratio.
Figure 4: PO2 levels over time. Treatment estimates (95% CI): 10 min post start
CPB GMR = 0.54 (0.43–0.68), 30 min post start CPB GMR = 0.93 (0.77–1.12), 10
min post end CPB GMR = 0.92 (0.63–1.35), 2 h in PICU GMR = 1.10 (0.81–1.48),
6 h in PICU GMR = 1.03 (0.78–1.37) and 24 h in PICU GMR = 1.07 (0.79–1.45).
Oxic-2 trial only. CI: confidence interval, CPB: cardiopulmonary bypass; GMR:
geometric mean ratio; PICU: paediatric intensive care unit; PO2: partial pressure
of oxygen.
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Follow-up to 1 year
Developmental assessments were carried out on 45 children (24
in the normoxic group and 21 in the hyperoxic group). The as-
sessment is scored in 5 domains, with higher scores indicating
more advanced development. No statistically significant differen-
ces were found between the 2 groups (Fig. 6, Supplementary
Material, Table S12 and S13). The primary analysis excluded
presurgery baseline assessments, which were only available for
20 children. Sensitivity analyses imputing missing baseline scores
and restricting the analysis to children with baseline assessments
did not substantially alter the treatment estimates or change
conclusions (Supplementary Material, Tables S14 and S15).
In the period from surgery to 1-year, a total of 51 serious ad-
verse events leading to prolonged hospitalization, hospital admis-
sion or death were reported in 22 patients in the normoxic
group compared 34 events in 12 patients in the hyperoxic group,
with infectious or respiratory-related events most commonly
reported (Supplementary Material, Table S16).
DISCUSSION
Together, the 2 Oxic trials provide a combined data set with suffi-
cient power for assessing the clinical effectiveness of controlled
reoxygenation in cyanotic infants and children undergoing
cardiac surgery. The combined results from the 2 trials suggest
that a surgical strategy in which the patient’s own preoperative
SaO2 level is maintained at the beginning of CPB and then slowly
increased in a controlled graded fashion is safe but with no
evidence of a clinical advantage over a strategy of maintaining
higher oxygen levels. Inotrope use, intubation time and postop-
erative stay were similar in the 2 groups, despite the longer aver-
age cross-clamp and CPB times in the normoxic group.
There is growing experimental and clinical evidence that reoxy-
genation injury in a cyanotic environment can be ameliorated by
reducing the oxygen levels on starting CPB and then gradually
increasing them in a staged manner, as demonstrated by a reduc-
tion in oxidative stress and organ injury [1–10, 13–15].
Nevertheless, there remains a lack of reliable data verifying
impaired organ function and biochemical parameters closely cor-
relates with poor surgical outcomes. Cyanotic infants and children
with congenital heart disease are more likely to suffer renal tubular
and glomerular injury, which is exacerbated by reoxygenation in-
jury and prolonged CPB duration [16–18]. Controlling reoxygena-
tion on starting CPB was associated with reduced renal damage in
the Oxic-2 trial (lower mean creatinine level on the second post-
operative day), confirming the organ protection capacity of this
strategy, possibly secondary to reduced oxidative stress [9, 19–21].
Potential concern about hypoxic injury to the brain induced
by the low PaO2 levels during CPB is not supported by the Oxic-
2 results, and the neurodevelopment assessments were similar in
the 2 groups. Furthermore, the cognitive, motor and adaptive be-
haviour scores were, on average, slightly higher in the normoxic
group, as were the language and social emotion scores up to
3 months, confirming the safety of controlled reoxygenation for
brain protection in cyanotic patients undergoing cardiac surgery.
Previous studies have shown that normoxic reperfusion on start-
ing CPB resulted in less myocardial injury as demonstrated by the
lower levels of markers such as CPK-MB and Troponin I [8–10, 21].
In vivo animal CPB models have also demonstrated improved ven-
tricular function with controlled reoxygenation reperfusion, but this
was not observed in Oxic-2 [7]. A possible explanation for this could
be that the assessments were based on routinely collected echocar-
diographic data; detailed parameters of ventricular dysfunction
measured in experimental animal settings were not collected.
Limitations
The study has strengths and limitations. Strengths include the
inclusive eligibility criteria, with few patients being ineligible
and minimization of bias through concealed allocation. Blood
samples were analysed in a single hospital laboratory, thereby
avoiding inter-laboratory variability, and laboratory personnel
conducting the analyses were blinded to the group allocation.
With respect to limitations, participants were recruited from a
single centre, thereby limiting the generalizability of the findings.
Figure 5: (A) Creatinine levels over time. Treatment estimates [95% confidence interval (CI)]: day 1 GMR = 0.95 (0.83–1.10), day 2 GMR = 0.86 (0.75–1.00), day 3 GMR
= 0.93 (0.80–1.08), day 4 GMR = 1.03 (0.89–1.20) and day 5 GMR = 1.02 (0.86–1.19). Oxic-2 trial only. (B) Urea levels over time. Numbers in brackets are the 95% CI.
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The primary outcome analyses included data from the 2 Oxic tri-
als conducted 10-years apart. The total sample was smaller than
planned (169 vs target 180 patients) which reduced the power
from 90% to 88%. Also, duration of inotropic support and sec-
ondary outcomes were only available in Oxic-2 reducing the
power of the study further to detect differences between the 2
groups. The primary clinical end points were also subject to vari-
ability in intra and postoperative care, but local protocols were
followed, and any differences should be balanced between
groups. Our failure to assess retinal damage as a possible marker
of reoxygenation injury is a further limitation. Early in the trial,
the serious adverse event classification of complications in the
Figure 6: Bayley developmental assessment composite scores. Oxic-2 trial only. CI: confidence interval; MD: mean difference.
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postoperative period was not collected, resulting in 56 events not
being graded. The lack of blinding of the operating room team is
inevitable, but nevertheless represents a weakness of the study.
CONCLUSION
Together, the Oxic-1 and Oxic-2 trials assessed the safety and
efficacy of controlled reoxygenation in cyanotic patients undergoing
cardiac surgery. The results support previous experimental and clin-
ical reports that controlled reoxygenation is safe, with no statistically
significant differences in clinical outcome between the 2 strategies.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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